GlassScriptPhysician profile
Kathleen Heffron
NPI 1295849677
$3,662.76
in general payments reported to CMS, 2019-2025
32 companies · $778 in 2025
The $778 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $595 · 2020: $210 · 2021: $357 · 2022: $521 · 2023: $754 · 2024: $448 · 2025: $778.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,980.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,979.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $818.96 | 2019-2023 | |
| Sumitomo Pharma America, INC. | $457.28 | 2023-2025 | Myfembree |
| Mayne Pharma Commercial LLC | $349.01 | 2023-2025 | |
| Astellas Pharma US INC | $274.27 | 2019-2024 | Veozah |
| Organon LLC | $229.94 | 2023-2025 | Nexplanon |
| Pfizer INC. | $218.91 | 2019-2025 | |
| Coopersurgical, INC. | $150.81 | 2020-2025 | Paragard T 380a, Endosee |
| Hologic Sales and Service, LLC | $144.45 | 2024-2025 | Fluent Fluid Management System, Myosure Tissue Removal Device, Omni Hysteroscope |
| Exeltis, USA INC. | $136.70 | 2019-2025 | Slynd |
| Amag Pharmaceuticals, INC. | $130.05 | 2019-2020 | |
| Vertex Pharmaceuticals Incorporated | $123.66 | 2025 | |
| Therapeuticsmd, INC. | $90.03 | 2019-2022 | |
| Myovant Sciences INC. | $87.18 | 2021-2022 | |
| Agile Therapeutics, INC. | $53.28 | 2021-2023 | Twirla |
| Millicent US INC | $47.11 | 2024-2025 | Intrarosa, Femring |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $41.53 | 2019 | |
| Minerva Surgical, INC | $37.06 | 2023 | |
| Sage Therapeutics, LLC | $27.27 | 2023-2024 | |
| Allergan, INC. | $26.29 | 2019-2020 | |
| Covidien LP | $25.30 | 2019 | |
| Daiichi Sankyo INC. | $24.92 | 2019 | |
| Mylan Pharmaceuticals INC. | $19.32 | 2022 | |
| Conmed Corporation | $19.15 | 2025 | Airseal |
| Vertical Pharmaceuticals, LLC | $16.67 | 2019 | |
| Axonics, INC. | $16.26 | 2024 | Bulkamid |
| Duchesnay USA Incorporated | $16.10 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.02 | 2022 | |
| Avion Pharmaceuticals | $14.57 | 2019 | |
| Coloplast Corp | $13.89 | 2024 | |
| Roche Diagnostics Corporation | $13.15 | 2019 | |
| Acessa Health INC. | $12.94 | 2019 | |
| Medtronic, INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathleen Heffron listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.